Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

John Carroll

Editor & Founder

Amber Tong

Five months after MyoKardia $MYOK swept its late-stage pivotal on its lead heart drug — highlighting its success with a precision med approach to cardiology …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

John Carroll

Editor & Founder

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

Editor & Founder

Sign up to read this article for free.

more like this

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout